Search

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

63.11 -1.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

62.74

Max

64.15

Belangrijke statistieken

By Trading Economics

Inkomsten

3M

-102M

EPS

-1.17

Werknemers

358

EBITDA

-7.6M

-112M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+23.11% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

471M

6B

Vorige openingsprijs

64.73

Vorige sluitingsprijs

63.11

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 aug 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 aug 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5 aug 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4 aug 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3 aug 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31 jul 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30 jul 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29 jul 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28 jul 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27 jul 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24 jul 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23 jul 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22 jul 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21 jul 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 jul 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

23.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 78 USD  23.11%

Hoogste 90 USD

Laagste 63 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat